Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Short-term debt obligations 3,585  4,819  3,862  3,346  569  545  381  1,703  1,620  1,716  1,925  987  1,461  1,306  1,197  992  990  155  106  139  642  755  330 
Accounts payable 2,441  2,852  3,069  2,445  1,888  2,005  1,976  1,892  1,773  1,873  1,725  2,248  1,699  1,551  1,503  1,664  1,407  1,504  1,543  1,565  1,249  1,839  2,346 
Other current liabilities 14,438  15,750  12,301  12,513  8,032  7,161  6,484  7,059  6,301  6,289  5,974  6,328  6,278  6,160  5,794  6,185  6,599  6,226  5,948  6,313  5,267  4,841  5,013 
Current liabilities 20,464  23,421  19,232  18,304  10,489  9,711  8,841  10,654  9,694  9,878  9,624  9,563  9,438  9,017  8,494  8,841  8,996  7,885  7,597  8,017  7,158  7,435  7,689 
Deferred income taxes 5,913  6,157  6,531  6,454  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Long-term debt, excluding current portion 41,364  41,853  42,844  43,387  24,390  24,433  5,635  5,646  5,687  5,671  5,775  6,975  6,982  6,911  7,237  5,716  5,836  6,581  6,593  6,550  6,632  6,615  7,127 
Other non-current liabilities 7,565  7,485  10,701  10,101  4,800  4,868  5,041  4,559  4,603  4,674  4,778  5,166  2,643  2,660  2,671  2,803  3,114  3,287  3,151  2,757  2,716  2,613  3,074 
Non-current liabilities 54,842  55,495  60,076  59,942  29,190  29,301  10,676  10,205  10,290  10,345  10,553  12,141  9,625  9,571  9,908  8,519  8,950  9,868  9,744  9,307  9,348  9,228  10,201 
Total liabilities 75,306  78,916  79,308  78,246  39,679  39,012  19,517  20,859  19,984  20,223  20,177  21,704  19,063  18,588  18,402  17,360  17,946  17,753  17,341  17,324  16,506  16,663  17,890 
Preferred stock —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Common stock 292  292  292  292  221  221  221  221  221  221  221  221  221  221  221  221  221  221  221  221  221  221  221 
Capital in excess of par value of stock 44,435  44,444  43,254  43,709  2,206  2,150  2,103  2,081  2,029  1,966  1,916  1,898  1,845  1,794  1,337  1,725  1,650  1,594  1,503  1,459  1,413  1,363  1,314 
Accumulated other comprehensive loss (1,699) (1,556) (1,549) (1,520) (1,463) (2,621) (2,644) (2,762) (2,326) (2,334) (2,234) (2,289) (2,421) (2,467) (2,414) (2,503) (2,735) (2,804) (2,693) (2,468) (2,395) (2,173) (2,416)
Retained earnings 32,414  31,565  32,671  34,474  36,555  35,870  35,109  34,065  33,292  32,044  32,323  31,160  34,141  33,934  33,658  33,513  33,272  32,706  32,176  31,613  32,446  32,361  33,110 
Cost of treasury stock (25,284) (25,651) (24,757) (25,357) (19,871) (19,571) (19,571) (19,574) (19,576) (19,580) (19,433) (19,249) (19,003) (18,783) (18,386) (16,779) (16,795) (16,799) (16,821) (16,559) (16,606) (16,649) (16,683)
Total Bristol-Myers Squibb Company shareholders’ equity 50,158  49,094  49,911  51,598  17,648  16,049  15,218  14,031  13,640  12,317  12,793  11,741  14,783  14,699  14,416  16,177  15,613  14,918  14,386  14,266  15,079  15,123  15,546 
Noncontrolling interest 72  66  66  100  106  102  99  96  110  101  113  106  131  122  119  170  168  160  165  158  194  168  143 
Total equity 50,230  49,160  49,977  51,698  17,754  16,151  15,317  14,127  13,750  12,418  12,906  11,847  14,914  14,821  14,535  16,347  15,781  15,078  14,551  14,424  15,273  15,291  15,689 
Total liabilities and equity 125,536  128,076  129,285  129,944  57,433  55,163  34,834  34,986  33,734  32,641  33,083  33,551  33,977  33,409  32,937  33,707  33,727  32,831  31,892  31,748  31,779  31,954  33,579 

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co.’s current liabilities increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current liabilities decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co.’s total liabilities decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Total Bristol-Myers Squibb Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co.’s total Bristol-Myers Squibb Company shareholders’ equity decreased from Q1 2020 to Q2 2020 but then increased from Q2 2020 to Q3 2020 exceeding Q1 2020 level.